Article
Virology
Carlos Solano de la Asuncion, Estela Gimenez, Juan Carlos Hernandez-Boluda, Maria Jose Terol, Eliseo Albert, Javier Lopez, Valentin Garcia-Gutierrez, Rafael Andreu, Maria Dolores Garcia Malo, Maria Laura Fox, Maria Jose Remigia, Paula Amat, Carlos Solano, David Navarro
Summary: This study investigated the dynamics of Torque Teno virus (TTV) DNA load in hematological patients treated with ibrutinib or ruxolitinib, and its predictive value for the occurrence of Cytomegalovirus (CMV) DNAemia and CMV-specific T-cell responses. The results showed that TTV DNA load was inversely correlated with absolute lymphocyte count, but it could not predict the occurrence of CMV DNAemia or the level of CMV-specific T-cell reconstitution. Despite the small sample size, further studies are needed to confirm these findings.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Pharmacology & Pharmacy
Steven B. Kleiboeker
Summary: Cytomegalovirus (CMV) is a significant human pathogen, with low but impactful prevalence of drug resistance mutations. In this study, 30.04% of patient samples showed resistance to one or more anti-CMV drugs, with most resistance mutations found in UL97. Rapid monitoring for resistance in suspected cases allows for tailored treatment based on objective results instead of empirical drug selection.
ANTIVIRAL RESEARCH
(2023)
Article
Immunology
Jiali Cheng, Jin Huang, Wenyue Cao, Liang Huang, Xia Mao, Liting Chen, Jianfeng Zhou, Na Wang
Summary: CMV infection/reactivation can occur in patients long after receiving anti-CD19/22 CAR-T cell therapy, and induce fatal pneumonia, which reminds us of the late side effects associated with immunosuppression after CAR-T cell infusion.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell & Tissue Engineering
Christine Camacho-Bydume, Audrey Mauguen, M. Irene Rodriguez-Sanchez, Elizabeth Klein, Nancy A. Kernan, Susan Prockop, Jaap Jan Boelens, Genovefa A. Papanicolaou, Maria Cancio
Summary: In pediatric patients undergoing TCD HSCT, early initiation of induction treatment after CMV reactivation is associated with improved overall survival (OS).
Article
Virology
Guy Shapira, Hadas Volkov, Itai Fabian, David W. Mohr, Maria Bettinotti, Noam Shomron, Robin K. Avery, Ravit Arav-Boger
Summary: This study identified genetic factors associated with protection against CMV infection in transplant recipients. A whole-exome association study was conducted in two cohorts of kidney transplant recipients, and several single-nucleotide polymorphisms (SNPs) were found to be significantly associated with protection from CMV DNAemia. Copy number variation of certain genes was also found to be significantly different between recipients with and without CMV DNAemia. These findings provide new predictive genetic markers for CMV infection protection.
Review
Immunology
Dipesh Kumar Yadav, Vishnu Prasad Adhikari, Rajesh Kumar Yadav, Alina Singh, Xing Huang, Qi Zhang, Prabesh Pandit, Qi Ling, Tingbo Liang
Summary: This meta-analysis compared the outcomes of antiviral prophylaxis and preemptive therapy for the prevention of cytomegalovirus (CMV) infection in liver transplant recipients. The results showed that antiviral prophylaxis reduced the incidence of CMV infection in the high-risk group, while preemptive therapy reduced the incidence of late-onset CMV disease. There were no significant differences in other outcomes between the two interventions.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
DeVon Hunter-Schlichting, Karl T. Kelsey, Ryan Demmer, Manish Patel, Raphael Bueno, Brock Christensen, Naomi Fujioka, Deepa Kolarseri, Heather H. Nelson
Summary: A study found that nearly half of malignant pleural mesothelioma patients have high level current HCMV infection, with a higher detection rate of HCMV DNA in tumor tissue compared to normal pleural tissue, suggesting the pleura may serve as a reservoir for latent HCMV infection.
Article
Surgery
Kristen G. Valencia Deray, Kathleen E. Hosek, Divya Chilukuri, Jordan R. Dunson, David R. Spielberg, Sarah J. Swartz, Joseph A. Spinner, Daniel H. Leung, Elizabeth A. Moulton, Flor M. Munoz, Gail J. Demmler-Harrison, Claire E. Bocchini
Summary: This study aimed to determine the frequency of CMV DNAemia in pediatric solid organ transplant recipients and found associations with high-risk CMV status and lung transplantation. The study showed that universal prophylaxis is effective in preventing CMV disease after SOTR, but further research is needed to optimize prevention strategies and reduce morbidity and mortality.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Article
Biophysics
Carlos Solano, Lourdes Vazquez, Estela Gimenez, Rafael de la Camara, Eliseo Albert, Montserrat Rovira, Ildefonso Espigado, Carmen Martin Calvo, Javier Lopez-Jimenez, Maria Suarez-Lledo, Anabella Chinea, Albert Esquirol, Ariadna Perez, Aranzazu Bermudez, Raquel Saldana, Inmaculada Heras, Ana Julia Gonzalez-Huerta, Tamara Torrado, Montserrat Batlle, Santiago Jimenez, Carlos Vallejo, Pere Barba, Maria angeles Cuesta, Jose Luis Pinana, David Navarro
Summary: Limited information is available on the impact of pre-engraftment CMV DNAemia on clinical outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT). This retrospective multicenter study involving 878 patients found that patients with pre-CMV DNAemia had a higher probability of recurrent episodes but comparable rates of CMV disease. Overall mortality and non-relapse mortality at 1-year after allo-HSCT were similar across patients with pre- and post-engraftment CMV DNAemia episodes.
BONE MARROW TRANSPLANTATION
(2021)
Article
Infectious Diseases
Caleb P. Skipper, Mark R. Schleiss
Summary: The role of CMV infection in the progression of HIV disease and other opportunistic infections is reviewed in this article. Clinical evidence suggests that CMV viremia is an independent risk factor for the progression of infections caused by C. neoformans and M. tuberculosis. Controlling CMV replication could reduce the risk of opportunistic infections, and the use of CMV antivirals is proposed for this purpose.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2023)
Article
Immunology
Alicja Sadowska-Klasa, Wendy M. Leisenring, Ajit P. Limaye, Michael Boeckh
Summary: A systematic review of randomized and observational studies from 2013-2023 indicated that antiviral preemptive therapy initiated at cytomegalovirus viral load thresholds between 2 and 3 log10 IU/mL had comparable cytomegalovirus disease rates. Thus, viral thresholds within this range appeared to effectively safeguard patients who did not receive prophylaxis.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Hematology
Alessandra Sperotto, Anna Candoni, Michele Gottardi, Gabriele Facchin, Rossella Stella, Roberta De Marchi, Angela Michelutti, Margherita Cavallin, Chiara Rosignoli, Francesca Patriarca, Renato Fanin
Summary: Reconstitution of T cells post-transplant is crucial for long-term success, and its correlation with CMV reactivation and disease is well-established. Pre-emptive antiviral treatment leads to faster T cell recovery, while prophylaxis with letermovir may result in CMV reactivation post-discontinuation, necessitating subsequent antiviral treatment.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Medicine, Research & Experimental
Qiqi Li, Quan Liang, Rongmei Meng, Qingqiao Xie, Yingzhen Zhang, Changjin Wei, Yunjie Wei, Kaiye He, Meihua Li
Summary: This study describes a case of cytomegalovirus (CMV) pneumonia combined with CMV DNAemia and CMV cystitis after hematopoietic stem cell transplantation (HSCT). The patient was treated with a combination of ganciclovir and foscarnet, along with immunoglobulin therapy, and was eventually cured and discharged.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2023)
Article
Multidisciplinary Sciences
Mulugeta Kiros, Alene Geteneh, Henok Andualem, Derbie Alemu, Abebech Tesfaye, Dessalegne Abeje Tefera, Adane Mihret, Dawit Hailu Alemayehu, Andargachew Mulu
Summary: This study aimed to investigate the prevalence of active HCMV infection among treatment-naive HIV-infected individuals in Ethiopia, finding a certain proportion of patients with active HCMV infection. However, no significant associations were found between dependent and independent variables. The presence of HCMV DNA highlights the necessity of routine laboratory diagnosis for preventing HCMV disease among HIV-infected individuals, and anti-CMV therapy for these individuals is recommended to reduce CMV complications and prolong their lifespan.
Article
Virology
Lynne Li, Christopher F. Lowe, Elizabeth McLachlan, Marc G. Romney, Alissa Wright, Nancy Matic
Summary: This study investigated CMV antiviral drug resistance (AVDR) frequencies in transplant patients in British Columbia, Canada from 2011 to 2019. The results showed that over half of the samples had AVDR mutations detected, with higher occurrence in solid organ transplant patients. Previous resistance testing was identified as a significant risk factor for AVDR. These findings can guide clinicians in selecting empiric antiviral therapy.
JOURNAL OF CLINICAL VIROLOGY
(2023)
Letter
Hematology
Michele Wieczorek, Myriam Labopin, Luca Castagna, Eolia Brissot, Gerard Socie, Anna Maria Raiola, Emanuele Angelucci, Arancha Bermudez Rodriguez, Ibrahim Yakoub-Agha, Mahmoud Aljurf, Charles Crawley, Jean Baptiste Mear, Maurizio Musso, Renato Fanin, Daniele Avenoso, Pascal Turlure, Cristina Tecchio, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Biophysics
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Thomas Schroeder, Nicolaus Kroeger, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Rose-Marie Hamladji, Victoria Potter, Ana Berceanu, Ibrahim Yakoub-Agha, Alessandro Rambaldi, Hakan Ozdogu, Jaime Sanz, Arnon Nagler, Mohamad Mohty
Summary: This study compared two different myeloablative conditioning regimens, FluTBI12 and FB4, before allo-HCT in AML patients. The results showed no significant differences in leukemia-free survival, overall survival, relapse incidence, and non-relapse mortality between the two groups. The incidence of acute and chronic GVHD also showed no statistical differences. In conclusion, FluTBI12 and FB4 are comparable myeloablative regimens for AML patients transplanted in CR1 and CR2.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Hematology
Solano de la Asuncion Carlos, Estela Gimenez, Juan Carlos Hernandez-Boluda, Maria Jose Terol, Eliseo Albert, Javier Lopez-Jimenez, Valentin Garcia-Gutierrez, Rafael Andreu, Dolores Garcia, Maria Laura Fox, Maria Jose Remigia, Paula Amat, Carlos Solano, David Navarro
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Rama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, Henrik Sengeloev, Tobias Gedde-Dahl, Aleksandr Kulagin, Uwe Platzbecker, Ibrahim Yakoub-Agha, Jenny L. Byrne, Thomas Valerius, Gerard Socie, Nicolaus Kroeger, Didier Blaise, Ali Bazarbachi, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: This retrospective study investigates the impact of time on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes for patients with acute myeloid leukemia (AML) in second complete remission (CR2). The results show that outcomes of allo-HCT in CR2 have significantly improved over time, with the most favorable outcomes achieved with a matched sibling donor (MSD).
Article
Oncology
Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermudez Rodriguez, Peter Remenyi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Summary: Comparing outcomes of adult patients with secondary acute myeloid leukemia (sAML) and de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) with post-transplant cyclophosphamide, no significant difference was observed in transplantation outcomes between the two groups.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
Philipp Berning, Norbert Schmitz, Maud Ngoya, Herve Finel, Ariane Boumendil, Fengrong Wang, Xiao-Jun Huang, Olivier Hermine, Laure Philippe, Lucile Couronne, Arnaud Jaccard, Daihong Liu, Depei Wu, Hans Christian Reinhardt, Yves Chalandon, Eva Wagner-Drouet, Mi Kwon, Xi Zhang, Ben Carpenter, Ibrahim Yakoub-Agha, Gerald Wulf, Javier Lopez-Jimenez, Jaime Sanz, Helene Labussiere-Wallet, Avichai Shimoni, Peter Dreger, Anna Sureda, Won Seog Kim, Bertram Glass
Summary: In this study, researchers conducted a retrospective analysis of data from 135 patients with natural killer/T-cell lymphomas (NKTCL) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). The results showed that allo-HSCT can achieve long-term survival in NKTCL patients.
Article
Oncology
Alvaro Diaz-Gonzalez, Elvira Mora, Gayane Avetisyan, Santiago Furio, Rosalia De la Puerta, Jose Vicente Gil, Alessandro Liquori, Eva Villamon, Carmen Garcia-Hernandez, Marta Santiago, Cristian Garcia-Ruiz, Marta Llop, Blanca Ferrer-Lores, Eva Barragan, Silvia Garcia-Palomares, Empar Mayordomo, Irene Luna, Ana Vicente, Lourdes Cordon, Leonor Senent, Alberto Alvarez-Larran, Jose Cervera, Javier De la Rubia, Juan Carlos Hernandez-Boluda, Esperanza Such
Summary: Cytogenetic assessment is crucial for myelofibrosis patients, but traditional techniques often fail to provide useful karyotypes. This study introduces optical genome mapping (OGM) as a promising method for high-resolution evaluation of chromosomal aberrations. OGM, combined with NGS, enabled risk classification in all cases, identifying additional cryptic aberrations and upgrading risk categories. The study highlights OGM as a valuable tool to improve disease risk stratification in myelofibrosis patients.
Article
Oncology
Lucia Perez-Lamas, Alejandro Luna, Concepcion Boque, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepcion Ruiz Nuno, Natalia de las Heras, Elvira Mora Castera, Javier Lopez Marin, Adrian Segura Diaz, Valle Gomez, Patricia Velez Tenza, Magdalena Sierra Pacho, Juan Antonio Vera Goni, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Patricia Carrascosa Mastell, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Raquel de Paz, Antonio Paz Coll, Maria Jose Fernandez, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Araceli Salamanca Cuenca, Antonio Jimenez-Velasco, Santiago Osorio Prendes, Marta Santaliestra, Maria Jose Lis Chulvi, Juan Carlos Hernandez-Boluda, Valentin Garcia-Gutierrez
Summary: After the introduction of asciminib as a treatment for chronic myeloid leukemia, there is still limited real-life data on its efficacy and toxicity profile. This study analyzed the toxicity profile of asciminib and its cross-toxicity risk with previous TKIs in patients with therapeutic failure. The results showed that asciminib has a good safety profile but may present a risk of cross-toxicity with classical TKIs for certain adverse effects.
Article
Hematology
Roni Tamari, Donal P. Mclornan, Kwang Woo Ahn, Noel Estrada-Merly, Juan Carlos Hernandez-Boluda, Sergio Giralt, Jeanne Palmer, Robert Peter Gale, Zachariah Defilipp, David I. Marks, Marjolein van der Poel, Leo F. Verdonck, Minoo Battiwalla, Miguel Angel Diaz, Vikas Gupta, Haris Ali, Mark Robert Litzow, Hillard M. Lazarus, Usama Gergis, Asad Bashey, Jane Liesveld, Shahrukh Hashmi, Jeffrey J. Pu, Amer Beitinjaneh, Christopher Bredeson, David Rizzieri, Bipin N. Savani, Muhammad Bilal Abid, Siddhartha Ganguly, Vaibhav Agrawal, Vera Ulrike Bacher, Baldeep Wirk, Tania Jain, Corey Cutler, Mahmoud Aljurf, Tamila Kindwall-Keller, Mohamed A. Kharfan-Dabaja, Gerhard C. Hildebrandt, Attaphol Pawarode, Melhem M. Solh, Jean A. Yared, Michael R. Grunwald, Sunita Nathan, Taiga Nishihori, Sachiko Seo, Bart L. Scott, Ryotaro Nakamura, Betul Oran, Tomasz Czerw, Ibrahim Yakoub-Agha, Wael Saber
Summary: A prognostic model was developed for myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. Factors such as patient age, donor compatibility, and hemoglobin levels were found to be associated with mortality risk. The proposed scoring system could accurately predict overall survival and transplant-related mortality in two large cohorts.
Article
Hematology
Gonzalo Carreno-Tarragona, Alberto Alvarez-Larran, Claire Harrison, Jose Carlos Martinez-avila, Juan Carlos Hernandez-Boluda, Francisca Ferrer-Marin, Deepti H. Radia, Elvira Mora, Sebastian Francis, Teresa Gonzalez-Martinez, Kathryn Goddard, Manuel Perez-Encinas, Srinivasan Narayanan, Jose Maria Raya, Vikram Singh, Xabier Gutierrez, Peter Toth, Paula Amat-Martinez, Louisa Mcilwaine, Magda Alobaidi, Karan Mayani, Andrew McGregor, Ruth Stuckey, Bethan Psaila, Adrian Segura, Caroline Alvares, Kerri Davidson, Santiago Osorio, Robert Cutting, Caroline P. Sweeney, Laura Rufian, Laura Moreno, Isabel Cuenca, Jeffery Smith, Maria Luz Morales, Rodrigo Gil-Manso, Ioannis Koutsavlis, Lihui Wang, Adam J. Mead, Maria Rozman, Joaquin Martinez-Lopez, Rosa Ayala, Nicholas C. P. Cross
Summary: Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are rare myeloid disorders with similar clinical presentations and outcomes. Mutational profiling revealed that both CNL and aCML have complex mutational profiles involving genes related to epigenetic regulation, splicing, and signaling pathways, with only EZH2 and TET2 differentially mutated between them. The study supports the idea that CNL and aCML are part of the same disease spectrum and highlights the importance of molecular-risk classification, particularly CSF3R mutations, in these diseases.
Correction
Oncology
Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermudez Rodriguez, Peter Remenyi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Hematology
Pedro Asensi Canto, Jaime Sanz Caballer, Pilar Solves Alcaina, Javier de la Rubia Comos, Ines Gomez Segui
Summary: The development and practical application of extracorporeal photopheresis (ECP) as a treatment for graft-versus-host disease (GVHD) is reviewed in this article, along with the underlying biological mechanisms. ECP reverses GVHD through lymphocyte apoptosis, modification of cytokine profiles, and changes in T cell subpopulations. However, logistical constraints may hinder the widespread use of this treatment.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Pedro Chorao, Juan Montoro, Aitana Balaguer-Rosello, Manuel Guerreiro, Marta Villalba, Ana Facal, Pilar Solves, Ines Gomez-Segui, Marcelo C. Pasquini, Pablo Granados, Ana Bataller, Alberto Louro, Javier de la Rubia, Miguel A. Sanz, Jaime Sanz
Summary: A study comparing bone marrow transplantation and peripheral blood transplantation for severe aplastic anemia found that peripheral blood transplantation led to faster recovery of bone marrow and platelets, as well as a lower incidence of acute GVHD. These findings suggest that peripheral blood could be a safer alternative to bone marrow for transplantation.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Chenyu Lin, Aurelie Schwarzbach, Jaime Sanz, Pau Montesinos, Patrick Stiff, Suhag Parikha, Claudio Brunstein, Corey Cutler, Caroline A. Lindemans, Rabi Hanna, Liang Piu Koh, Madan H. Jagasia, David Valcarcel, Richard T. Maziarz, Amy K. Keating, William Y. K. Hwang, Andrew R. Rezvani, Nicole A. Karras, Juliana F. Fernandes, Vanderson Rocha, Isabel Badell, Ron Ram, Gary J. Schiller, Leonid Volodin, Mark C. Walters, Nelson Hamerschlak, Daniela Cilloni, Olga Frankfurt, Joseph P. McGuirk, Joanne Kurtzberg, Guillermo Sanz, Ronit Simantov, Mitchell E. Horwitz
Summary: This article reports on the long-term effects of ex vivo-expanded cellular therapy using umbilical cord blood in 105 patients with hematologic malignancies or sickle cell hemoglobinopathy. The results show that 5% of the patients experienced secondary graft failure within 12 months, but no late cases occurred, and stable trilineage hematopoiesis and immune function were observed during long-term follow-up.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Mohamed A. Kharfan-Dabaja, Myriam Labopin, Ernesto Ayala, Ali Bazarbachi, Didier Blaise, Jan Vydra, Stefania Bramanti, Maija Itala-Remes, Christoph Schmid, Alessandro Busca, Edouard Forcade, Werner Rabitsch, Marco Zecca, Nicolaus Kroeger, Claude-Eric Bulabois, Giovanni Grillo, Alessandro Rambaldi, Renato Fanin, Francesco Zallio, Nicola Di Renzo, Yener Koc, Yana Novis, Andrew McDonald, Concepcion Herrera Arroyo, Jaime Sanz, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Summary: The study evaluated the impact of HLA mismatches on post-allograft outcomes in haploidentical allo-HCT for acute myeloid leukemia. The results showed that the extent of HLA disparity did not affect the incidence of acute and chronic graft-versus-host disease. Overall survival, leukemia-free survival, and relapse incidence were similar between the groups.
